These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20436503)

  • 1. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.
    Allred DC
    Mod Pathol; 2010 May; 23 Suppl 2():S52-9. PubMed ID: 20436503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
    Marotti JD; Collins LC; Hu R; Tamimi RM
    Mod Pathol; 2010 Feb; 23(2):197-204. PubMed ID: 19898422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.
    Rao PS; Labhart M; Mayhew SL; Thirumala S; Rao US
    Tumour Biol; 2014 Jul; 35(7):7267-73. PubMed ID: 24777335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
    Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
    Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.
    Bieche I; Parfait B; Le Doussal V; Olivi M; Rio MC; Lidereau R; Vidaud M
    Cancer Res; 2001 Feb; 61(4):1652-8. PubMed ID: 11245479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Risk Stratification for Breast Cancer Samples Based on the Expression Ratio of the Estrogen and Progesterone Receptor.
    Bendrat K; Fritz P; Müller S; Brockmöller S; Debus A; Friedrichs K; Lindner C; Brinkmann F; Heidemann E; Niendorf A
    Anticancer Res; 2016 Aug; 36(8):3855-63. PubMed ID: 27466487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERα-36 regulates progesterone receptor activity in breast cancer.
    Konan HP; Kassem L; Omarjee S; Surmieliova-Garnès A; Jacquemetton J; Cascales E; Rezza A; Trédan O; Treilleux I; Poulard C; Le Romancer M
    Breast Cancer Res; 2020 May; 22(1):50. PubMed ID: 32429997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some DCIS is different molecularly from DCIS with co-existing IDC.
    Steinman S; Bourne P; Yang Q; Tang P; Wang J
    Breast J; 2008; 14(1):122-3. PubMed ID: 18186882
    [No Abstract]   [Full Text] [Related]  

  • 10. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.
    Niemeier LA; Dabbs DJ; Beriwal S; Striebel JM; Bhargava R
    Mod Pathol; 2010 Feb; 23(2):205-12. PubMed ID: 19898421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas).
    Rakha EA; Ellis IO; Reis-Filho JS
    Mod Pathol; 2008 Aug; 21(8):1060-1; author reply 1061-2. PubMed ID: 18654595
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer.
    Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Fu P; Honda Y; Iyama K; Iwase H
    Mod Pathol; 2013 Jan; 26(1):79-86. PubMed ID: 22918168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    Schrijver WAME; Suijkerbuijk KPM; van Gils CH; van der Wall E; Moelans CB; van Diest PJ
    J Natl Cancer Inst; 2018 Jun; 110(6):568-580. PubMed ID: 29315431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium.
    Rokicki J; Das PM; Giltnane JM; Wansbury O; Rimm DL; Howard BA; Jones FE
    Mol Cancer; 2010 Jun; 9():150. PubMed ID: 20550710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein microarray-based comparison of HER2, estrogen receptor, and progesterone receptor status in core biopsies and surgical specimens from FFPE breast cancer tissues.
    Berg D; Langer R; Tran K; Walch A; Schuster T; Bronger H; Becker KF
    Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):300-5. PubMed ID: 21293257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast tumours following combined hormone replacement therapy express favourable prognostic factors.
    Borgquist S; Anagnostaki L; Jirström K; Landberg G; Manjer J
    Int J Cancer; 2007 May; 120(10):2202-7. PubMed ID: 17278089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
    Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
    Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR expression and activation are common in HER2 positive and triple-negative breast tumours.
    Koletsa T; Kotoula V; Karayannopoulou G; Nenopoulou E; Karkavelas G; Papadimitriou CS; Kostopoulos I
    Histol Histopathol; 2010 Sep; 25(9):1171-9. PubMed ID: 20607659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
    Lee JY; Won HY; Park JH; Kim HY; Choi HJ; Shin DH; Kang JH; Woo JK; Oh SH; Son T; Choi JW; Kim S; Kim HY; Yi K; Jang KS; Oh YH; Kong G
    J Clin Invest; 2015 May; 125(5):1801-14. PubMed ID: 25822021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
    Leary AF; Drury S; Detre S; Pancholi S; Lykkesfeldt AE; Martin LA; Dowsett M; Johnston SR
    Clin Cancer Res; 2010 Mar; 16(5):1486-97. PubMed ID: 20179226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.